Publication | Closed Access

Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study

MedicinePathologyBronchial NeoplasmFirst-line TreatmentCancer TreatmentOncologyRadiation OncologyLung CancerMolecular OncologyCancer GrowthErlotinib Versus Chemotherapy